SCHEMBL2836152

SCHEMBL2836152

C[C@@H](N)C1CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2842886 1.00
SCHEMBL1020014 1.00
SCHEMBL6853792 0.97 EPHX1 (0.43)
SCHEMBL22191947 0.97 EPHX1 (0.43)
SCHEMBL56860 0.97
Hydrochloric Acid SCHEMBL15663093 0.97
Hydrochloric Acid SCHEMBL1984857 0.97
SCHEMBL22606844 0.97 EPHX1 (0.43)
SCHEMBL3052722 0.97 EPHX1 (0.43)
SCHEMBL55861 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2809655-B1 BENZIIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER (US) 2015-08-12 EP disclosed
US-8927587-B2 Chemical compounds PFIZER LIMITED (GB) 2015-01-06 US disclosed
US-20130274243-A1 Chemical Compounds PFIZER LTD (GB) 2013-10-17 US disclosed
WO-2013114250-A1 BENZIIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER INC. (US) 2013-08-08 WO disclosed
WO-2011103441-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS SCHERING CORPORATION (US) 2011-08-25 WO disclosed
EP-2266951-A1 Organic compounds Novartis AG (CH) 2010-12-29 EP disclosed
US-7851642-B2 δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compound NOVARTIS AG (CH) 2010-12-14 US disclosed
US-20090253701-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-10-08 US disclosed
US-20090253703-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-10-08 US disclosed
US-7582782-B2 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (1-hydroxymethyl-cyclopentyl)-amide; hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, alzheimers NOVARTIS AG (CH) 2009-09-01 US disclosed
EP-1725570-B1 PROCESS FOR THE PRODUCTION OF ASYMMETRIC TRANSFORMATION CATALYSTS PHOENIX CHEMICALS LTD (GB) 2008-08-13 EP disclosed
US-20070135498-A1 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (1-hydroxymethyl-cyclopentyl)-amide; hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, alzheimers NOVARTIS AG (CH) 2007-06-14 US disclosed
WO-1994002441-A1 A PROCESS FOR MAKING 1-CYCLOPENTYLALKYL AMINES USEFUL FOR THE SYNTHESIS OF SWEETENERS THE COCA-COLA COMPANY (US) 1994-02-03 WO disclosed
US-5225591-A One-step reduction of an azanorbornene THE COCA-COLA COMPANY (US) 1993-07-06 US disclosed